Risk of higher purchase prices resulting from changes in rebates and allowances
First written in FY2021. . Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Increase in unsettled amountsAnnual report
「(Unsettled allowance amount in the wholesale business for prescription pharmaceuticals and other products for the fiscal year ending March 2026: ¥20.434 billion).」
The unsettled allowance amount increased to ¥20.434 billion from ¥17.984 billion in the previous fiscal year. The risk of changes in business practices due to changes in pharmaceutical companies' sales strategies continues. - FY2025Increase in unsettled amountsAnnual report
「(Unsettled allowance amount in the wholesale business for prescription pharmaceuticals and other products for the fiscal year ended March 2025: ¥17.984 billion).」
The unsettled allowance amount increased to ¥17.984 billion from ¥16.567 billion in the fiscal year ended March 2024. The risk of changes in business practices due to changes in pharmaceutical companies' sales strategies continues. - FY2024Decline in unsettled amountsAnnual report
「(Unsettled allowance amount in the wholesale business for prescription pharmaceuticals and other products for the fiscal year ended March 2024: ¥16.567 billion).」
The unsettled allowance amount declined from ¥18.568 billion in the previous fiscal year to ¥16.567 billion. The risk of changes in business practices due to changes in pharmaceutical companies' sales strategies continues. - FY2023Decline in unsettled amountsAnnual report
「(Unsettled allowance amount in the wholesale business for prescription pharmaceuticals and other products for the fiscal year ended March 2023: ¥18.568 billion).」
The unsettled allowance amount was ¥18.568 billion, down from ¥19.415 billion in the fiscal year ended March 2022. The risk of changes in business practices due to changes in pharmaceutical companies' sales strategies continues. - FY2022Slight decline in unsettled amountsAnnual report
「(Unsettled allowance amount in the wholesale business for prescription pharmaceuticals and other products for the fiscal year ended March 2022: ¥19.415 billion)」
The unsettled allowance amount declined from ¥19.675 billion in the previous fiscal year to ¥19.415 billion, but the risk of changes in business practices due to changes in sales strategies continues. - FY2021First statedAnnual report
「Business practices with pharmaceutical companies and others include rebates and allowances that effectively reduce purchase prices (unsettled allowance amount in the wholesale business for prescription pharmaceuticals and other products for the fiscal year ended March 2021: ¥19.675 billion). If pharmaceutical companies and others make significant changes to their sales strategies, resulting in changes to these business practices, the performance and financial condition of the wholesale business for prescription pharmaceuticals and other products may be affected.」
The unsettled allowance amount of ¥19.675 billion was disclosed, and changes in rebate and allowance business practices resulting from changes in pharmaceutical companies' sales strategies were disclosed as a new risk.